RDY - Dr. Reddy's Laboratories Limited

NYSE - NYSE Delayed Price. Currency in USD
42.00
-0.35 (-0.83%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close42.35
Open42.35
Bid41.98 x 800
Ask42.00 x 900
Day's Range41.85 - 42.56
52 Week Range34.67 - 42.91
Volume172,021
Avg. Volume166,132
Market Cap6.979B
Beta (5Y Monthly)-0.20
PE Ratio (TTM)29.91
EPS (TTM)1.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 12, 2018
1y Target Est36.75
  • Top Pharmaceutical Stocks for Q1 2020
    Investopedia

    Top Pharmaceutical Stocks for Q1 2020

    The pharmaceutical business is part of the larger healthcare sector. Pharmaceutical products may be generic, such as those used for common ailments like the flu and colds, or branded, patented drugs used for treating rare diseases including certain types of cancers. Among the best-known pharmaceutical companies are Eli Lilly & Co. (LLY) and Merck & Co. (MRK).

  • New Strong Sell Stocks for January 10th
    Zacks

    New Strong Sell Stocks for January 10th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Business Wire

    Dr. Reddy's to Release Q3 FY 20 results on January 27, 2020  Earnings Call Slated for January 27, 2020 @ 6:30 PM IST / 8:00 AM EST

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the third quarter ended December 31, 2019 on Monday, January 27, 2020 after the Board Meeting.

  • Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial, the therapeutic generic equivalent of Nitropress® (sodium nitroprusside) Injection, 50 mg/2mL vial, approved by the U.S. Food and Drug Administration (USFDA).

  • Amarin Stock is at Sky-High Levels Already Assumes All the Good News
    InvestorPlace

    Amarin Stock is at Sky-High Levels Already Assumes All the Good News

    On Friday, Dec. 13, 2019, the FDA approved an expanded cardiovascular claim for Vascepa, a drug produced by Amarin (NASDAQ:AMRN). Prior to this patients with very high triglyceride levels were only ones approved to use Vascepa.Source: Pavel Kapysh / Shutterstock.com Now those with lower levels and other signs of heart or diabetes issues can use it. This vastly expands the population to whom Amarin can sell Vascepa. Those with greater than 150 milligrams per deciliter can now use the drug. Amarin estimates that "millions" (with no specific number associated with that noun) can benefit from its drug.A previous advisory committee had unanimously recommended that the drug be approved. There was a high likelihood that the FDA would approve Vascepa for expanded cardiovascular treatment.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amarin Stock Includes a Lot of Good NewsAnalysts have already argued that Amarin's Vascepa, its only drug, will bring in greater than $1 billion annually in sales, with peak sales above that. One analyst, Nathan Weinstein, at Aegis believes the drug could hit $2 billion in sales by 2025. His peak price target was $23 per share.The problem is Amarin stock is already very close to that target price, at $21.36 per share. In other words, a lot of the good news is already implied in the valuation of AMRN stock. Another analyst, at Stifel, has put a hold recommendation on Amarin stock. His price target is $28 per share. * 7 'Strong Buy' Stocks to Put on Your Wish List Amarin announced that it expects its 2020 U.S. sales to be between $650 million to $700 million from sales of Vascepa. Seeking Alpha's database of eight analysts have an average estimate of $692 million in revenue for 2020.That puts Amarin stock on a forward price-to-sales ratio of 11.9 times. That is an extremely high valuation metric. It would normally be the number for a conservative stock's price-to-earnings ratio.It implies that a bidder for all of AMRN stock would have to wait almost 12 years before their investment would equal the sales achieved, not earnings. Not too many companies would be willing to do that.Clearly the market expects that sales will climb significantly over the next 12 years. There are tw0 problems with that theory: competition and patent issues. Problems With the ValuationThe FDA is also looking at similar drug studies from: AstraZeneca (NYSE:AZN), whose drug is called Epanova; Acasti Pharma (NASDAQ:ACST), with CaPre; and, Matinas BioPharma (NYSEAMERICAN:MTNB), with its MAT900i drug.A recent analyst article in Seeking Alpha assessed these three competitors and the state of play of their drug applications. The analysts considered these companies competitive threats to Amarin and its Vascepa drug.In addition, Amarin is facing patent lawsuits from several companies. These include Dr. Reddy's Laboratories (NYSE:RDY), an Indian pharmaceutical company, and Hikma Pharmaceuticals (OTCMKTS:HKMPY), a generic pharma company. However, bullish analysts point out that Teva (NYSE:TEVA) has already settled with Amarin.Most of these suits, including one that begins in January, concern the validity of the core of Amarin's patent family. It is called "Methods for treating hypertriglyceridemia." Another patent for "Stable pharmaceutical composition and methods of using same" family is also in litigation. * 5 Large-Cap Dividend Stocks to Buy If Amarin loses these cases, it could lose all patent protection. Other drug companies could use their ideas.As it stands the patents give Amarin protection until 2029, or 10 years. This is Amarin's only product, so it has to make hay during that period with Vascepa. What Should Investors Do?AMRN is a high-risk, high-return stock. As always, I recommend only buying on dips and during bad news with these kinds of stocks. They are essentially a mild form of gambling, although some risks can be minimalized with probability analysis.Given that a prior panel recommended for Vascepa, the AMRN stock price already discounted last week's FDA good news. Analysts seem to agree. Their target values are not significantly higher than the present price.Investors should look for an opportune time to jump in. Analysts will likely scrutinize the patent protection litigation closely in January. Look for an opportunity then to consider investing in Amarin stock.As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Mark Hake runs the Total Yield Value Guide which you can review here. The Guide focuses on high total yield value stocks. Subscribers a two-week free trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Biggest Investing Surprises of 2019 * 7 Impressive Stocks to Buy Over $250 * 4 Small-Cap Energy Stocks Ready to Explode The post Amarin Stock is at Sky-High Levels Already Assumes All the Good News appeared first on InvestorPlace.

  • Hedge Funds Are Piling Into Dr. Reddy’s Laboratories Limited  (RDY)
    Insider Monkey

    Hedge Funds Are Piling Into Dr. Reddy’s Laboratories Limited (RDY)

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Deferasirox Tablets for Oral Suspension, in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade® (deferasirox) Tablets for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

  • Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Deferasirox Film-Coated Tablets, in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Jadenu® (deferasirox) Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the U.S. Food and Drug Administration (USFDA).

  • Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. today announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U.S.

  • Business Wire

    Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. today announced the launch of Doxercalciferol Injection, 4 mcg/2 mL Multiple-Dose Vials, the therapeutic generic equivalent of Hectorol® Injection 4 mcg/2 mL Multiple-Dose Vials, approved by the U.S.

  • New Strong Sell Stocks for November 15th
    Zacks

    New Strong Sell Stocks for November 15th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • New Strong Sell Stocks for November 11th
    Zacks

    New Strong Sell Stocks for November 11th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
    Zacks

    Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

    Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

  • Business Wire

    Dr. Reddy’s Q2 & H1 FY20 Financial Results

    Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards .

  • Business Wire

    Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. confirms it had initiated a voluntary nationwide recall on October 1, 2019, of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine above levels established by the FDA.

  • Hedge Fund Sentiment Unchanged On Dr. Reddy’s Laboratories Limited (RDY)
    Insider Monkey

    Hedge Fund Sentiment Unchanged On Dr. Reddy’s Laboratories Limited (RDY)

    We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Dr. Reddy's Laboratories Limited (NYSE:RDY) based on […]

  • Business Wire

    Dr. Reddy's to release Q2 FY 20 results on November 1, 2019

    Earnings call slated for November 1, 2019 @ 6:30 PM IST / 9:00 AM EDT

  • Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
    Zacks

    Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

    Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

  • The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
    Zacks

    The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

    The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

  • BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%
    Zacks

    BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

    BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Foamix Initiates Phase II Study on Acne Combination Foam
    Zacks

    Foamix Initiates Phase II Study on Acne Combination Foam

    Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

  • Is it Apt to Foray Into the Indian Stock Market?: An Analysis
    Zacks

    Is it Apt to Foray Into the Indian Stock Market?: An Analysis

    The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.

  • J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
    Zacks

    J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

    J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

  • Zynerba Releases Data on Epilepsy Candidate, Stock Down
    Zacks

    Zynerba Releases Data on Epilepsy Candidate, Stock Down

    Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

  • Top Ranked Momentum Stocks to Buy for September 17th
    Zacks

    Top Ranked Momentum Stocks to Buy for September 17th

    Top Ranked Momentum Stocks to Buy for September 17th